For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Stage-Based Mobile Intervention for Substance Use Disorders in Primary Care: Implementation and Cluster-Randomized Trial

    SBC: Pro-Change Behavior Systems Inc            Topic: NIDA

    Nearlymillion Americans ageand olderneed treatment for a substance use disorderSUDWhile onlyof individuals requiring treatment for a SUD receive itan estimated two thirds see a primary care or urgent care provider everymonthsPrimary care providers are in a unique position to perform ScreeningBrief Interventionand Referral to TreatmentSBIRTWith Phase I contract fundingPro Change developed and pilot ...

    SBIR Phase I 2018 Department of Health and Human Services
  2. A cost-effective robotic platform for on-demand production of flexibly dosed medications in a chewable gummy dosage form

    SBC: Vitae Industries, Inc.            Topic: NICHD

    PROJECT SUMMARYThis project s goal is to develop an innovative cost effective robotic platform for fast on demand pharmacy production of pediatric drugs as individually tailored palatable gummy dosage formsMedication adherence is notoriously low among children due to difficulty swallowing pills and rejection of bad tasting medicationsAlthough some common pediatric drugs have flavored liquid formsp ...

    SBIR Phase I 2018 Department of Health and Human Services
  3. Caring for the Caregiver: A Theory-Driven Mobile Intervention to Promote Caregiver Well-Being

    SBC: Pro-Change Behavior Systems Inc            Topic: NIA

    Overmillion Americans are currently providing unpaid care to a family memberrelativeor friend with Alzheimer s disease or related dementiaWhile caregiving can be a positive experience that brings meaning and an increased sense of purposeit can also take a tollNearlyof Alzheimer s and dementia caregivers rate their emotional distress as high or very highand as many assuffer from depressionCaregiver ...

    SBIR Phase I 2018 Department of Health and Human Services
  4. 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN: A Phase II Clinical Trial in Adolescents/Young Adults (AYA)with CNS Malignancies

    SBC: DEKK-TEC INC            Topic: 102

    AbstractThe goal of this Phase II clinical trial application will be to evaluatedemethylcholesteryloxycarbonylpenclomedineDM CHOC PENas anticancer therapy for adolescents and young adultsAYAwith cancer involving the brain in a Phase II clinical trialDM CHOC PENFigis a polychlorinated pyridine cholesteryl carbonateFigthat is lipophilicelectrically neuralis able to cross the blood brain barrierBBBlo ...

    SBIR Phase II 2018 Department of Health and Human Services
  5. Rapid Test to Assist Therapy in Neonatal Sepsis and Necrotizing Enterocolitis

    SBC: PROTHERA BIOLOGICS, LLC            Topic: R

    The primary goal of this proposed research is to develop a rapid point of care test that assesses the risk of neonatal sepsisNSand or necrotizing enterocolitisNECin infants based on Inter alpha inhibitor proteinsIAIPlevels in bloodThe test is expected to be simpleuser friendlyportable and suitable for use in the NICUNS and NEC are associated with high mortality and morbidityincluding adverse neuro ...

    SBIR Phase I 2018 Department of Health and Human Services
  6. Double Chimeric Peptide Vaccine Feasible for Human Use that Protects against Disseminated Candidiasis caused by medically important Candida species

    SBC: Autoimmune Technologies, LLC            Topic: NIAID

    PROJECT ABSTRACT The goal of this Phase I STTR proposal is to develop and establish preclinical proof of concept for the first double chimeric peptide vaccine feasible for human use that protects against disseminated candidiasisDisseminated candidiasis is the third leading cause of nosocomial bloodstream infections in the USwithcases per year and associated healthcare costs of $billionanddespite t ...

    STTR Phase I 2018 Department of Health and Human Services
  7. Evaluation of oral oleocanthal to prevent and/or treat Alzheimer's disease and related dementias

    SBC: Oleolive, LLC            Topic: NIA

    PROJECT SUMMARY Alzheimer s diseaseADis a progressive neurodegenerative disorder of the elderly that afflicts aboutmillion patients globally and overmillion Americans in the USDespite the considerable research effort to preventtreator cure the diseaseeffective strategies remain lackingThe accumulation of amyloidAin the brain blood vessels can result in the development of cerebral amyloid angiopath ...

    SBIR Phase I 2018 Department of Health and Human Services
  8. SnapCap: a device to decontaminate central venous catheters (CVC) with 5 snaps

    SBC: Contech Medical, Inc.            Topic: NICHD

    Project Summary Abstract We propose a new approach to the decontamination of central venous catheters and the prevention of central line associated bloodstream infectionsCLABSIan important healthcare associated infectionCLABSIs cost the US healthcare system approximately $billion annuallyPronovostNEJMAdditionallyCLABSIs can be life threateningespecially in the very young and critically illEven whe ...

    STTR Phase I 2018 Department of Health and Human Services
  9. Galectin-1 Protein Therapy for Congenital Muscular Dystrophy


    Abstract Lamininrelated congenital muscular dystrophyLAMACMDalso known as Merosin Deficient Congenital Muscular DystrophyMDC Ais a fatal muscle wasting disease that affects patients from birthLAMACMD results from mutations in the LAMAgene resulting in loss of lamininproteinLamininis required for the formation of the heterotrimers lamininand lamininwhich are major constituents of the skeletal and c ...

    STTR Phase I 2018 Department of Health and Human Services
  10. IND-Enabling Studies of ZB716, an Orally Bioavailable SERD

    SBC: Zenopharm, LLC            Topic: 102

    Project Summary Fulvestrant is the only FDA approved selective estrogen receptor downregulatorSERDindicated for advanced metastatic breast cancer that has progressed after or during tamoxifen or aromatase inhibitorAItreatmentIn July and Augustfulvestrant was approved as a first line endocrine agent for breast cancer patients by the European Medicines AgencyEMAand US FDArespectivelyHoweverthe drug ...

    SBIR Phase II 2018 Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government